amgen continues to make all-time highs, reasonable valuation, tremendous pipeline. just some good news on the fda front. i think amgen can go higher fro here there are deals taking place and i think the stocks relatively speaking, the ones with the pipelines, are still very inexpensive. to answer your original question, absolutely, yes. >> i think we're back to those days where people are starting to look for their -- they say it would have cost us at least that much if not more to get to this point. talking about a billion and a half, $2 billion to get to some of these the area everybody wants to go, roche made a deal, novartis made a deal there's all kinds of deals anywhere around $9 billion and below. there are companies out in the biotech space that will stand alone. i think it's the amgens of the world. >> they're huge. >> biogen still trades at a ten multiple this is a biotech and they're still involved and hoping for good results for alzheimer's. >> i've got this big old screen here, steve grasso, that has 100 plus biotechs. about half are up and half are dow

what do you think of amgen it's up 20% ford future. >> amgen did something i made a lot of money with amgen but not enough that was because we did not think the market was reacting correctly to getting otezla so cheaply. it's moving up as much as you said if you want to buy amgen buy it at 210 and i would take it because it's a much better company than it was six months ago. let's go to austin in florida. austin. >> caller: happy holidays. boo-yah. >> that was sweet. right back >> caller: jim, you got me started in caterpillar, cat. i've got a good amount of it what do we do with it? >> i think you want to sell some trade around it if you are a trader and buy it back later why do i say that? because i don't think caterpillar is going to have a good quarter and i am worried about more tariffs if you want to make money, it's up a lot and buy it back let's go to randy in ohio. randy. >> caller: jim, biomed hired two research firms to test their otella turns out they're 22, 29% more safer than aortic balloons they use them on older, sicker patients and half would die if they didn't use th

jenny, to you from franklin in new york amgen, should i stay long?> sure, so, we're long amgen in our portfolio, it's trading cheap. 15 times earnings, high single-digit earnings are for the next few years there's a push between existing drugs and revenues in our case, we're holding to it and we might trim it if we need to buy something new and use it as a source of funds >> shannon to you, from tom. what do you think of valero in 2020 >> performers outperformed this year with the energy and the play on shale. i think if you look at valero over the next few years, they have several projects coming online between now and 2022. it's a great yield for investors between the share buyback and dividend yields. i would bite uy it for 20 went. >> jimmy, coming to you from gabby in staten island is bank of america at these levels a buy or sell >> hi, i like bank of america here i think bank and citigroup are one of these with jpmorgan the money center banks will appreciate as the yield curve continues to steepen a little bit and rates go a little higher havin

and we've been adding to th names we think have the potential next year in healthcare, things like amgen or cvs on the healthcare side. i think that's the version that's going to take place in 2020. >> david, mer christmas and year new >> likewise, right back a you, bill. >> thanks david. >>> is the finalew hours before christmas, and the last big shopping push is on. could be big. retail world as super saturday, it's estimated sales reached more than $34 billion. and while a consumer is driving its economy, the way we spend did it 20 years ago.hit than we >> reporter: everyone else is focused on ristmas present, i'm here to talk a ctmas past. let's rewind the clock to 1999. how are consumers were spending their money? online shopping bely registered back then. the national retail federation hadn't beg tracking international sales. now it's forecasted to reach $157 billion this holiday. it would help drive sales to another record high. >> this holiday season is looking to be our best i years. this past saturday was a single strongest shopping day of the season. all early indicators are s

amgen is the big weight. the exbi equal weight. a sector lagged triple the market market up 6 it's up 20 the past two months and this part hotter in certain names. and every day new news it feels peak -- >> the real thing to consider on options trade are you actually spending some money betting on something happening? or are you collecting money kind of expecting something not to happen here if it continues to contend with this high, then it's going to languish along here that means little is going to happen by selling a call spread you look to get paid for that nothing to happen. and if it declines -- >> what's the risk on that selling the call spread. >> the risk is of course. >> the call spread. >> the risk you are taking is the difference between the strikes which is a dollar 67 and the 70 cents you collect basically, you know, you're not risking a great deal but the risk happens if it actually in turn breaks out. but it has to break out in within the next month because that's when it expires. >> that's a good discussion. i lea

i amgen fer casarian and i work here at san francisco international airport. the idea for therapy dogs got started the day after 9/11. an employee brought his therapy dog to work after 9/11 and he was able to see how his dog was able to relieve passenger's jitter. when we first launched the program back in 2013, our main goal was to destress our passengers however what we quickly found is that our animals were helping us find a way to connect with our pang. passengers. we find there are a lot of people traveling through the airport who are missing their pets and who are on their road a lot and can't have pets and we have come in contact with a lot of people recently who have lost pet. >> i love the wag brigade. >> one of my favorite parts is walking into the terminals and seeing everybody look up from their device, today everybody is interacting on their cell phone or laptop and we can walk into the terminal with a dog or a pig and people start to interact with each other again and it's on a different level. more of an emotional level. >> i just got off an 11.

this to treat a wide variety of ailments and big pharma agrees with them they have partnerships with amgen and j&j. the company kept putting up positive clinical trial data so i felt comfortable enough to give it my blessing. a month ratlater we checked in h the ceo right before the company's big r&d day. he told a terrific story listen to this. >> i think what they saw was a powerful technology that as you say can silence genes. it is a hyper specific process whereby we can psy linsz a single jean. we've got three of them in phase three trials as well as two partner programs in phase two. the stock caught fire and arrowhead made appearances at a series of health care conferences always with bullish data and applauded by the money managers in the room they got attention by the analyst community and as they get discovered by wall street, they are roaring higher as one economic analyst gets behind them first one of arrowhead's main competitors got bought by novartis while the actual numbers don't really matter for early stage biotech management, they confirmed they'd be putting two more drug

studies show they aren't losing market share as rapidly as they thought and they are going out buying amgen month and that's a $15 billion a year company to replace the sales they think they are going to lose due to humira, so management has gone to great lengths to handle their problems and i think they have more than adequately plus it pays a 5.3% dividend yield. susan: you have to. carrying debts as well as those levels. wondering about your choice in cvs viacom. you're the second person within the half hour, last 15 minutes. >> really? susan: recommended shari redstone's company. >> this is one of my favorites. they are counting on $500 million worth of cost synergies due to the merge. increased size and scale, they are going to be able to increase licensing, distribution, production, all these things will come together, i believe to work for them. it is 26 billion-dollar a year company. maybe $10 billion worth of debt. susan: yes. >> my base case scenario is multiple expansion. my best-case scenario, somebody with a lot of cash and not enough on streaming service we could use those guy

october of 1961 it's going into marriott, it's going into alphabet, it's going to apple, allergan, amgen. >> what did i just say there you go take a shot. new highs. money coming in a lot of diverse places in the market and sectors. >> that's very healthy, very broad-based. that's what you want to see. cutting through a lot of unknowns in terms of trade and brexit and fed and the budget. i've said before i think we are priced at this multiple at about 18 times we are pricing in a lot of good news however, i do think now we shift to growth and global growth, like kourtney was just talking about. you are seeing brother growth. not great but improving. by the way, the data points today we got was very encouraging with regards to housing, industrial production i know industrial production was benefited from the gm coming back, but i do think you're seeing business cap ex within industrial production actually showing improvement. so that's encouraging. >> that's a good point speaking of encouraging, sorry to jump in fourth quarter gdp a few weeks ago was expected to be pretty lousy. now it's

. >> cgrp, amgen has one those are monthly -- allergen which is merging with advi has a once a day pillould be different from those. would the fda say someone like me can't take it >> this is different because we're trying to destruct this place. we're the only company that has this quick dissolve, orderly dissolving tablet. where you put in your mouth. it quickly disperses and has a very quick onset of action then lasts for a couple of days. it's an oral, simple-to-use pill it's not a needle or injectable. so that's where we are going to disrupt the space little bit with this unique approach. we're the only company looking to use this pill at this dose for both acute and prevention of migraine. >> don't get me excited. you know i care so much about this disease and i don't want anyone to get their hopes up because there is 30 million surfers and the medical community has not been good until recently. >> we think we're on to something here and we hope we can bring a better treatment to patients in the first quarter of 2020. where we expect our nda approval. >> that's huge it could be re

october up 26% and it's 4% basically year to date if you bought the ibb, you're up 24% and you get amgen text lumina and biogen in the top holdings. >> and agree with that except for the fact that the ibb is up 25 peppers in the 40 sessions and back at 120 resistance after drastically underperforming the s&p hon relatively bays from the early part of the year it's now right in hine with the 2-year average i wonder whether this is a recalibration that had the time. >> allison heim esper absolutely the holy grail in the space without question but i think now you know the downside in biogen pch it's 225 or there abouts. injury the downside is more than the 5% or 10% they mentioned but i think the upside if they get it right and it's not happening tomorrow or next week but if they get alzheimer's right the stock is daubl despite the outcome the last couple weeks i think the move is upside. >> for the good of a lot of people investors primed to get big news tomorrow but will it be good news traders in the options market may have itright the right the answer would be a resounding no mike khouw

what happened between our generation gen x and millennial amgen z, assuming we can use those terms puttinghe monastic, what happened? what changed? >> to be honest, i'm still trying to figure that out. i can answer that by backing up a little bit and talking about how i came to approach this. this book had so many iterations like initially it was going to be all about feminism. it was only going to be it was going to be called, you are not a bad ass and it was good to be called you are probably not a bad ass. i assumed hillary clinton was à would be present.that didn't happen and the conversation around social justice issues and the culture wars brought it out into inner sexuality whatever that means, we can get into that. the topic had to go beyond women but i will say in trying to figure out the answer to that question i had to think about the fact that i grew up right alongside second wave feminism. i was born in 1970 i was three years old when roe v wade past i remember being 12 years old in 1982 and sitting at the kitchen table with my mother listening to npr, not c-span, npr. hearing

up 51% and amgen up 20%.panies are looking to boost the pipelines with more innovative assets and technol y technology. acquisitions obviously make it more desirable because they allow big pharma to have complete control and that bodes well for the future of m & a activity in pharma. neil: it's certainly picking up the pace. thank you very, very much. >>> meantime, the department of homeland security announcing a surprising drop at the number of apprehensions along the u.s./mexico border. we have all the details on that. hey, william. reporter: apprehensions down 70% from just six months ago. why? three things. mexico is doing more on enforcement. they are also sheltering more asylum seekers there, not here. that is putting on the brakes, eliminating the incentive for many migrants to even come to the u.s. >> it's a crisis that's not manufactured. it is real. reporter: without congressional action, officials feared nothing could stem the flow of migrants fleeing the violence in south america and mexico. >> yo

you're going with the old guard of amgen, biogen, and gilead why? >> that's right.rge caps have generally underperformed the midbiotechs, which are the one drug ponies which if it works, you get paid a lot. i cover the larger cap names and among those, it's a powerful of products, sometimes pay a dividend and are able to, you know, do well, even if the overall market does not do particularly well. so that is the logic behind those choices. >> very good ronny gal from bernstein, good to see you again good to see you. >> check, please! is next. ♪ ♪ ♪ ♪ ♪ ♪ don't get mad. get e*trade, dawg. through the at&t network, edge-to-edge intelligence gives you the power to see every corner of your growing business. from using feedback to innovate... to introducing products faster... to managing website inventory... and network bandwidth. giving you a nice big edge over your competition. that's the power of edge-to-edge intelligence. it's finally time for... geico sequels! classic geico heroes, starring in six new commercials, with jaw-dropping savings. vote for your favorites a